TARIS Biomedical, which focuses on developing new treatments for urologic diseases, has secured $32 million in funding.
Tag: Flagship Ventures
Editas Medicine, a leading genome editing company, raised $120 million in a highly oversubscribed Series B private financing. It is noted that Editas is translating the promise of CRISPR/Cas9 technology into a new class of transformative genomic medicines to treat a broad range of diseases by enabling precise and corrective molecular modifications to treat disease […]
The amount of 40 million dollars was raised recently from Joule Unlimited, a biofuels company. The funding round was led by Flagship Ventures, and till today the startup has raised a total funding of more than $200 million. Joule Unlimited is years away from commercializing its process in which bacteria are injected into outdoor units […]
Having received an initial investment commitment of 217 million dollars, Denali Therapeutics, a new biotechnology company focused on developing effective therapies for neurodegenerative diseases launched its services. Among the founding investors of the company are Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund. Denali Therapeutics is based on the collaboration of […]